Novocure (NVCR) Reports Phase 3 METIS Trial Met Primary Endpoint

Go back to Novocure (NVCR) Reports Phase 3 METIS Trial Met Primary Endpoint
(NASDAQ: NVCR) Delayed: 13.11 -1.06 (7.48%)
Previous Close $14.17    52 Week High $28.95 
Open $12.60    52 Week Low $5.95 
Day High $13.85    P/E N/A 
Day Low $11.85    EPS $0.00 
Volume 5,955,757